GU Cancers Symp. 2014: Prostate Cancer Immunotherapy

GU Cancers Symposium 2014 - Clinical and biologic factors for immune response to sipuleucel-T for metastatic castrate-resistant prostate cancer - Poster February 4, 2014

GU Cancers Symposium 2014 - CCP score and risk stratification for prostate cancer patients at biopsy - Poster February 4, 2014

GU Cancers Symposium 2014 - Effect of prior abiraterone or enzalutamide on sipuleucel-T manufacture in PROCEED patients - Poster January 31, 2014

GU Cancers Symposium 2014 - Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥ 80 years-old: Data from PROCEED - Poster January 31, 2014

GU Cancers Symposium 2014 - Impact of prior radiation treatment on sipuleucel-T product parameters in PROCEED patients - Poster January 31, 2014

GU Cancers Symposium 2014 - Antigen spread and survival with sipuleucel-T in patients with advanced prostate cancer - Poster January 31, 2014

GU Cancers Symposium 2014 - New developments in immunotherapy for metastatic prostate cancer - Session Highlights January 31, 2014

GU Cancers Symposium 2014 - Peptide vaccines with low-dose dexamethasone versus dexamethasone alone for chemotherapy-naive castration resistant prostate cancer: A randomized phase II study - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Unleashing the power of the immune system through combination therapy - Session Highlights January 30, 2014